Business Segments · D&A
Life Sciences — D&A
Becton, Dickinson and Company Life Sciences — D&A increased by 2.3% to $45.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 2.3%, from $44.00M to $45.00M. Over 3 years (FY 2021 to FY 2024), Life Sciences — D&A shows a downward trend with a -8.2% CAGR.
Analysis
How to read this metric
Rising levels often correlate with a growing asset base, whereas stable levels suggest a consistent investment profile.
Detailed definition
This metric represents the non-cash expense allocated to the Life Sciences segment for the wear and tear of tangible ass...
Peer comparison
Depreciation levels are typically benchmarked against total segment revenue or total asset value to assess capital intensity relative to peers.
Metric ID:
bdx_segment_life_sciences_depreciation_and_amortizationHistorical Data
16 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $88.00M | $88.00M | $70.75M | $70.75M | $70.75M | $70.75M | $69.25M | $69.25M | $69.25M | $69.25M | $68.00M | $68.00M | $68.00M | $68.00M | $44.00M | $45.00M |
| QoQ Change | — | +0.0% | -19.6% | +0.0% | +0.0% | +0.0% | -2.1% | +0.0% | +0.0% | +0.0% | -1.8% | +0.0% | +0.0% | +0.0% | -35.3% | +2.3% |
| YoY Change | — | — | — | — | -19.6% | -19.6% | -2.1% | -2.1% | -2.1% | -2.1% | -1.8% | -1.8% | -1.8% | -1.8% | -35.3% | +2.3% |
Range$44.00M – $88.00M
CAGR-16.4%
Avg YoY Growth-7.3%
Median YoY Growth-2.1%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Becton, Dickinson and Company's life sciences — d&a?
- Becton, Dickinson and Company (BDX) reported life sciences — d&a of $45.00M in Q4 2025.
- How has Becton, Dickinson and Company's life sciences — d&a changed year-over-year?
- Becton, Dickinson and Company's life sciences — d&a increased by 2.3% year-over-year, from $44.00M to $45.00M.
- What is the long-term trend for Becton, Dickinson and Company's life sciences — d&a?
- Over 3 years (2021 to 2024), Becton, Dickinson and Company's life sciences — d&a has grown at a -8.2% compound annual growth rate (CAGR), from $352.00M to $272.00M.
- What does life sciences — d&a mean?
- The non-cash expense representing the gradual loss of value of the Life Sciences segment's assets.